EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Shares in PharmaMar crashed after the Spanish biotech revealed a phase 3 ovarian cancer trial had missed its primary endpoint. Synthetic tetrahydroisoquinoline alkaloid Zepsyre failed to improve progression-free survival in patients with platinum-resistant ovarian cancer. Statement (PDF)

> Ablynx named Robert Friesen, Ph.D., as its CSO. Friesen joins from ProQR at a time when Ablynx is the subject of takeover interest from Novo Nordisk. Release

> BioCanCell unveiled plans to list its stock in the U.S. The Israeli biotech revealed its IPO intentions in a statement about the pricing of a $25 million (€20 million) financing round. Statement

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

> Advicenne followed up on its IPO by appointing Linda Law, M.D., to oversee its U.S. clinical trial activities. Release

> Genfit kicked off its pediatric NASH program. Statement

> ImmuPharma raised £10 million ($14 million). Release